[123I/18F] N-(2-aminoethyl)-5-halogeno-2-pyridinecarbox-amides, site specific tracers for MAO-B mapping with SPECT and PET

H F Beer; L D Frey; M Häberli; P A Schubiger

doi:10.1016/0969-8051(95)02022-5

[123I/18F] N-(2-aminoethyl)-5-halogeno-2-pyridinecarbox-amides, site specific tracers for MAO-B mapping with SPECT and PET

Nucl Med Biol. 1995 Nov;22(8):999-1004. doi: 10.1016/0969-8051(95)02022-5.

Authors

H F Beer¹, L D Frey, M Häberli, P A Schubiger

Affiliation

¹ Radiopharmacy Division, Paul Scherrer Institute, Villigen, Switzerland.

PMID: 8998478
DOI: 10.1016/0969-8051(95)02022-5

Abstract

After the successful 123I-labelling of Ro 43-0463 the new radiopharmaceutical was tested in animals and humans. Both investigations proved the binding of the labelled compound to cerebral MAO-B. SPECT investigations resulted in an imaging of the MAO-B distribution in the human brain. This prompted us to develop the labelling of this type of MAO-B inhibitor with 18F enabling us to transfer our results to PET.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Autoradiography
Brain / anatomy & histology
Brain / enzymology*
Brain Mapping / methods*
Fluorine Radioisotopes
Humans
Iodine Radioisotopes
Isotope Labeling
Monoamine Oxidase / metabolism*
Monoamine Oxidase Inhibitors / chemical synthesis*
Pyridines / chemical synthesis*
Pyridines / pharmacology
Radioactive Tracers*
Rats
Tomography, Emission-Computed
Tomography, Emission-Computed, Single-Photon

Substances

Fluorine Radioisotopes
Iodine Radioisotopes
Monoamine Oxidase Inhibitors
Pyridines
Radioactive Tracers
Monoamine Oxidase